Биржевые новости

новости каждый час
Mind Medicine announces 1-for-15 reverse stock split
Mind Medicine (NASDAQ:MNMD) on Thursday announced a 1-for-15 reverse stock split. As a result of the stock split, there will be ~28.4M shares issued and outstanding. The stock split aims to address Nasdaq's minimum bid price requirement. The stock split is expected to take effect after close of business on Aug. 26. MNMD shares edged 3.8% lower aftermarket following the announcement.
05 Августа, 2022г., 03:16
Hot Stocks: CCXI doubles on AMGN takeover deal; CI hits 52-week high; SITM, BALL plunge on earnings
cemagraphics The major U.S. equity averages posted a mixed performance on Thursday, as investors bided their time ahead of a key employment report due out before Friday's open. The Nasdaq edged higher, while the Dow and S&P 500 dipped. Although most of the market saw lackluster trading, ChemoCentryx (NASDAQ:CCXI) had a breakout session. Shares more than doubled after the company agreed to a takeover deal with Amgen (AMGN). Meanwhile, Cigna (CI) rode a strong earnings report to a new 52-week high. On the other side of the spectrum, SiTime (SITM) lost more than a third of its value after the company indicated that its market has softened dramatically in the last few months. At the same time, earnings news sent Ball (BALL) to a new 52-week low. Standout Gainer News of a takeover deal sent ChemoCentryx (CCXI) soaring, with the stock finishing higher by about 110%. The advance came as Amgen (AMGN) agreed to purchase the drug developer in a transaction valued at $3.7B. Under the agreement, CCXI shareholders will receive $52 per share in cash. The deal is expected to close in Q4. CCXI finished Thursday's trading at $50.43, an advance of $26.32. Shares also reached a new intraday 52-week high of $50.90. Shares had fallen from a level around $39 in early January to a 2022 closing low of $15.36 on May 9. Standout Loser Shares of SiTime (SITM) cratered 35% after the company was forced to roll back a guidance increase it announced three months ago because of a deteriorating economic situation. The technology company, which specializes in silicon MEMS timing solutions, reported Q2 results that beat analysts' expectations, including revenue that jumped 78% from last year. However, shares plummeted on the firm's outlook. Back in May, the firm raised its forecast for annual growth from 35% to 50%. As it announced its latest earnings report, SITM reverted to its original forecast, saying it will likely see growth of around 35% for the year. "In May, when we increase our guidance from 35% to 50% annual growth, we did not anticipate the subsequent conditions, financial downturn, supply chain disruptions and political turmoil, all of which made it difficult for our customers to see the magnitude and the speed of decline in their own business," CEO Rajesh Vashist said in a conference call the company hosted following the release of its financial figures. SITM dropped $73.11 to close at $136.40. Going into the earnings report, the stock had been gaining ground, coming off a 52-week low of $129.44 reached in about a month ago. Thursday's retreat largely reversed this recent upswing. Notable New High The release of better-than-expected earnings and raised guidance drove a 3% advance in shares of health insurer Cigna (CI). With the uptick, the stock set a new 52-week high. The company reported adjusted earnings that climbed 19% from last year, helped by a 5% advance in revenue. Both results exceeded expectations. Meanwhile, CI increased its revenue forecast for 2022, saying it expects at least $178B for the year. Analysts are looking for a figure around $179B. On the earnings front, CI projected adjusted EPS of at least $22.90, above the $22.74 that analysts were looking for. Bolstered by the earnings news, CI surged to an intraday 52-week high of $284.46. Shares moderated a bit from there, eventually finishing at $280.10, an advance of $8.36 on the day. The latest rise took the stock just above a closing high reached last month, adding to gains posted through much of the first half of the year. Shares have climbed about 25% in the last six months. Notable New Low Ball (BALL) tumbled to a new 52-week low following the release of disappointing earnings. The weak bottom line prompted a decline of almost 19%. The aluminum packaging products supplier reported a quarterly profit that came in below the amount analysts were predicting. At the same time, the company pointed to a slowing of customer demand amid high inflation. "Segment volumes were flat in the second quarter and reflect the deceleration of customer demand resulting from significant retail pricing actions by customers to pass through inflationary costs to consumers, particularly in the U.S.," the company said. On the earnings news, BALL dropped $13.52 to close at $59.28. During the session, the stock also reached an intraday 52-week low of $58.67. Thursday's slide took the stock below a recent trading range, adding to the weakness seen earlier in the year. Shares have now fallen about 36% in 2022. To see more of Wall Street's biggest winners and losers, click over to Seeking Alpha's On The Move section.
05 Августа, 2022г., 03:16
Black Diamond Group declares CAD 0.015 dividend
Black Diamond Group (OTCPK:BDIMF) declares CAD 0.015/share quarterly dividend, in line with previous. Forward yield 1.51% Payable Oct. 15; for shareholders of record Sept. 30; ex-div Sept. 29. See BDIMF Dividend Scorecard, Yield Chart, & Dividend Growth.
05 Августа, 2022г., 03:16
Bionano stock down ~8% after hours; co reports Q2 revenue beat, wider loss
JuSun Shares of small-cap pharmaceutical company Bionano Genomics (NASDAQ:BNGO) fell 8.1% to $2.16 in Thursday postmarket trading, after the genome analysis firm reported a wider Q2 loss and a significant fall in quarterly gross margin. It is worth noting that BNGO stock had gained 27% since Tuesday and posted a three-day winning streak at today's close. BNGO announced Q2 net loss of $32.16M compared to a loss of $18.79M last year. However, its revenue of $6.67M grew a healthy 72.8% Y/Y and beat estimates by $0.39M. The company said the quarterly figure was an all-time high for it. Revenue growth was aided by expansion of the installed base of BNGO's Saphyr sytems and a 24% Y/Y rise in sales of nanochannel array flowcells. The company's bottom line was hurt due to a 87.2% Y/Y rise in total operating expenses to $33.55M. BNGO CEO Erik Holmlin said that the company remained on track to achieve its previously outlined ELEVATE! milestones for the second half of the year. Bionano Geonomics (BNGO) stock has lost 21.4% YTD.
05 Августа, 2022г., 03:16
Hawaiian Electric declares $0.35 dividend
Hawaiian Electric (NYSE:HE) declares $0.35/share quarterly dividend, in line with previous. Forward yield 3.29% Payable Sept. 9; for shareholders of record Aug. 18; ex-div Aug. 17. See HE Dividend Scorecard, Yield Chart, & Dividend Growth.
05 Августа, 2022г., 03:16
Icahn Enterprises scores a revenue beat in Q2 even with investment losses
Neilson Barnard Icahn Enterprises (NASDAQ:IEP) Q2 revenue topped Wall Street expectations after the investment firm run by Carl Icahn recorded a net loss from investment activities during a quarter marked by market volatility. Q2 total revenue of $3.50B, topping the $2.65B consensus, slipped from $4.08B in Q1 and increased from $2.99B in the year-ago quarter. Net sales of $3.80B increased from $2.97B in the prior quarter and from $2.61B in the year-ago period. Net loss from investment activities was $442M compared with net gain of $939M in Q1 and net gain of $206M in the the same quarter a year ago. Q2 expenses of $3.79B climbed from $3.10B in Q1 and $2.99B in Q2 2021; costs of goods sold increased to $3.17B from $2.54B in the prior quarter and from $2.40B a year earlier. Q2 adjusted EBITDA attributable to IEP fell to $126M from $616M in the prior quarter and $192M in the year-ago quarter. Indicative net asset value of $6.58B at June 30, 2022 compares with $6.23B at March 31. Earlier, Icahn Enterprises GAAP EPS of -$0.41, revenue of $3.5B beats by $850M
05 Августа, 2022г., 03:16
Atlassian taps former Microsoft exec as CFO
Sundry Photography/iStock Editorial via Getty Images Atlassian (NASDAQ:TEAM) has tapped Joe Binz as its new CFO and Principal Financial Officer. Binz, who has held finance roles at Microsoft (MSFT) and Intel (INTC) previously, will join Atlassian (TEAM) on September 6, 2022. He brings over 25 years of finance leadership and experience to the role. Since 2014, Binz served as Corporate Vice President, Finance at Microsoft. In other news, Atlassian (TEAM) delivered better-than-expected Q4 results today Shares have gained over 10% on the earnings news  
05 Августа, 2022г., 03:15
Invesco Mortgage Q2 mixed as agency mortgage values weakened by rising yields
deepblue4you/E+ via Getty Images Invesco Mortgage Capital (NYSE:IVR) Q2 results came in mixed as its book value was hampered by a slump in agency mortgage valuations amid the Federal Reserve's rate hiking campaign. "While our outlook on valuations remains cautious in the near term, we expect the environment for Agency RMBS to improve later this year given the attractiveness of spreads relative to other fixed income sectors and the decline in mortgage origination," said CEO John Anzalone. Adjusted EPS of $1.40 at the end of June exceeded the average analyst estimate of $0.83 and climbed from $1.16 at March 31 and $0.96 at June 30, 2021. Net interest income for Q2 was $41.1M, missing the consensus of $44.0M and sliding from $44.3M in Q1 and $46.3M in Q2 2021. Net interest margin rose 93 basis points to 3.48% in Q2 vs. Q1, mostly due to higher average earning asset yields. Book value of $16.16 per share in Q2 vs. $20.78 a year ago. In the wake of rising interest rate across the board, the mortgage REIT's leverage was lowered. Debt-to-equity ratio was 3.4x as of June 30, compared with 5.2x as of March 31. Earlier, Invesco Mortgage Capital raised its dividend to $0.905 per share.
05 Августа, 2022г., 03:15
Corteva posts Q2 beat, lifts guidance on record demand for grains, oilseeds
moiseXVII/iStock via Getty Images Corteva (NYSE:CTVA) +5% post-market on Thursday after topping expectations for Q2 adjusted earnings and revenues, while raising full-year guidance, citing strong demand for its crop protection products. Q2 net income rose to $1.58B, or $2.16/share, from $1.02B, or $1.37/share, in the year-earlier quarter, as sales increased 11% to $6.25B from $5.63B a year ago. Q2 net seed sales rose 4% Y/Y to $3.95B as a 7% increase in prices more than offset a 1% drop in volumes, with global corn and soybean pricing 6% and 8%, respectively. Q2 crop protection sales jumped 25% to $2.3B, driven by a 14% increase in volume and 14% higher prices, boosted by strong market penetration by Corteva's (CTVA) Enlist herbicide and Onmira fungicide, coupled with strong early demand in Latin America. Corteva (CTVA) raised FY 2022 guidance for adjusted EPS of $2.45-$2.60 from $2.35-$2.55, in line with $2.50 analyst consensus estimate, on revenues of $17.2B-$17.5B, up from 16.7B-17B and exceeding $16.96B consensus. The company said it expects record demand for grain and oilseeds in 2022, and said grower balance sheets and income levels remain healthy despite higher input costs for fuel and fertilizer. Corteva's (CTVA) stock price return shows a 17% Y/Y gain and a 30% increase during the past year.
05 Августа, 2022г., 03:15
CareDx stock slumps 14% as net loss widens, FY22 outlook slashed
Zerbor CareDx (NASDAQ:CDNA) stock fell ~14% post-market Aug. 4 after Q2 results missed estimates and the company lowered its FY22 revenue outlook, which was seen below expectations. Q2 Non-GAAP net loss widened to -$7.01M, compared to -$5.88M, in the prior year period. Meanwhile, total revenue increased +9% Y/Y to $80.63M. Both top and bottom line missed analysts estimates. Testing services revenue grew +3.46% Y/Y to $67.14M. However, Product revenue declined -2.14% Y/Y to $6.71M. Patient and digital solutions revenue grew +178.42% to $6.79M. Adjusted EBITDA was a loss of -$5.73M, compared to an adjusted EBITDA gain of $6.81M in Q2 2021. As of June 30, cash, cash equivalents and marketable securities were $306.2M. Outlook: For the full year 2022, CareDx said it was is revising its revenue expectations to be in the range of $325M to $335M (Consensus Revenue Estimate for 2022 $337.96M) due to higher than expected mix of commercial patients from the success of new launches and market expansion. In May, the company had said it expected revenue to be in the range of $330M to $350M. CDNA -13.58% to $21.00 post market Aug. 4.
05 Августа, 2022г., 03:15
iHeartMedia reports Q2 results; sees Q3 revenue growth guidance below estimates
iHeartMedia press release (NASDAQ:IHRT): Q2 GAAP operating income of $83M vs. $28M in Q2 2021. Consolidated Adjusted EBITDA of $237M increased 29% Y/Y; in line with guidance of $225M to $245M Revenue of $954.01M (+10.7% Y/Y) misses by $1.89M. Guidance: Q3 Consolidated Revenue expected to increase by approximately 3%-7% Y/Y vs. estimated growth of 9.52% Y/Y; Q3 Consolidated Adjusted EBITDA expected to be $240 million to $255 million.
05 Августа, 2022г., 03:15
HYZN, CLFD and ZFOX are among after hour movers
GAINERS: Progyny (PGNY) +17%. Atlassian Corporation  (TEAM) +10%. Lyft (LYFT) +9%. Clearfield (CLFD) +8%. iHeartMedia (IHRT) +7%. LOSERS: Hyzon Motors  (HYZN) -25%. CareDx (CDNA) -14%. Warner Bros. Discovery (WBD) -12%. Momentive Global (MNTV) -12%. ZeroFox Holdings  (ZFOX) -10%.
05 Августа, 2022г., 03:15